ABC Arbitrage SA Takes Position in CVS Health Corporation $CVS

ABC Arbitrage SA acquired a new stake in CVS Health Corporation (NYSE:CVS) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 5,343 shares of the pharmacy operator’s stock, valued at approximately $384,000.

A number of other large investors have also added to or reduced their stakes in CVS. Vanguard Group Inc. lifted its holdings in shares of CVS Health by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 120,709,530 shares of the pharmacy operator’s stock worth $9,579,508,000 after purchasing an additional 1,824,424 shares during the period. State Street Corp increased its holdings in CVS Health by 2.1% in the fourth quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator’s stock valued at $4,776,182,000 after purchasing an additional 1,245,457 shares during the period. Capital International Investors raised its position in CVS Health by 3.4% during the 4th quarter. Capital International Investors now owns 27,592,356 shares of the pharmacy operator’s stock worth $2,189,793,000 after purchasing an additional 900,153 shares during the last quarter. Norges Bank acquired a new position in CVS Health during the 4th quarter worth about $1,666,265,000. Finally, Morgan Stanley grew its position in shares of CVS Health by 6.3% in the 4th quarter. Morgan Stanley now owns 20,373,774 shares of the pharmacy operator’s stock valued at $1,616,863,000 after buying an additional 1,211,631 shares during the last quarter. Institutional investors own 80.66% of the company’s stock.

Analyst Upgrades and Downgrades

CVS has been the subject of several recent research reports. HSBC reissued a “hold” rating and issued a $103.00 price target on shares of CVS Health in a research note on Monday, July 6th. Cantor Fitzgerald upped their target price on CVS Health from $100.00 to $110.00 and gave the company an “overweight” rating in a report on Tuesday, July 7th. Morgan Stanley raised their price target on shares of CVS Health from $106.00 to $111.00 and gave the stock an “overweight” rating in a report on Thursday, June 4th. Truist Financial boosted their price target on shares of CVS Health from $108.00 to $118.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Mizuho increased their price objective on shares of CVS Health from $110.00 to $115.00 and gave the stock an “outperform” rating in a research report on Monday, June 8th. Twenty-one equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $104.04.

Insider Buying and Selling at CVS Health

In other CVS Health news, EVP Tilak Mandadi sold 69,551 shares of the firm’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the transaction, the executive vice president directly owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. This trade represents a 87.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Larry Robbins sold 1,983,538 shares of CVS Health stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the transaction, the director owned 6,213,261 shares of the company’s stock, valued at $586,842,501.45. This represents a 24.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 3,441,551 shares of company stock worth $323,703,977. Corporate insiders own 0.85% of the company’s stock.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Truist raised CVS Health’s price target to $118 from $108 and kept a buy rating, signaling more upside from current levels.
• Positive Sentiment: CVS Caremark announced an agreement with the FTC that it says will improve transparency and affordability in prescription drug pricing, which may help reduce regulatory overhang and support investor confidence. Article Title
• Positive Sentiment: Management also highlighted GLP-1 support expansion across CVS pharmacies, MinuteClinic, and virtual channels, which could strengthen its healthcare services offering and drive more consumer traffic. Article Title
• Neutral Sentiment: Commentary from Jim Cramer and several value-oriented articles reinforced the view that CVS remains a popular large-cap healthcare stock, but these pieces are more sentiment-driven than fundamentally new.
• Negative Sentiment: The FTC settlement also underscores continued scrutiny of CVS Caremark’s rebate and pricing practices, including changes to how it handles drug rebates and future TrumpRx deductible credits, which could pressure margins or business terms over time. Article Title

CVS Health Stock Up 0.2%

Shares of NYSE:CVS opened at $106.11 on Wednesday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. CVS Health Corporation has a 52-week low of $58.50 and a 52-week high of $106.93. The business’s 50 day simple moving average is $97.87 and its two-hundred day simple moving average is $84.60. The firm has a market cap of $135.39 billion, a P/E ratio of 46.74, a PEG ratio of 1.04 and a beta of 0.61.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating the consensus estimate of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The firm had revenue of $100.43 billion during the quarter, compared to the consensus estimate of $94.99 billion. During the same quarter in the previous year, the company posted $2.25 earnings per share. The company’s quarterly revenue was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, research analysts forecast that CVS Health Corporation will post 7.44 EPS for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd will be issued a dividend of $0.665 per share. The ex-dividend date is Thursday, July 23rd. This represents a $2.66 annualized dividend and a yield of 2.5%. CVS Health’s dividend payout ratio is presently 117.18%.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.